Data on this page show the responses of individuals who received the Moderna monovalent Omicron XBB.1.5 (registered for use in people aged 12 years and over) COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. These data give a profile of what to expect in the days following Moderna XBB.1.5 COVID-19 vaccination and can assist when planning for your Moderna XBB.1.5 COVID-19 vaccination. Data on this page are updated monthly.


AusVaxSafety’s active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website.
Click here to view ATAGI’s recommendations on the use of XBB.1.5 COVID-19 vaccines

Last updated January 2024